CN101195032B - 聚天冬酰胺衍生物与阿霉素偶联物的制备方法及其应用 - Google Patents
聚天冬酰胺衍生物与阿霉素偶联物的制备方法及其应用 Download PDFInfo
- Publication number
- CN101195032B CN101195032B CN2007101922251A CN200710192225A CN101195032B CN 101195032 B CN101195032 B CN 101195032B CN 2007101922251 A CN2007101922251 A CN 2007101922251A CN 200710192225 A CN200710192225 A CN 200710192225A CN 101195032 B CN101195032 B CN 101195032B
- Authority
- CN
- China
- Prior art keywords
- phea
- suc
- gal
- drug
- dox
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001597008 Nomeidae Species 0.000 title claims description 7
- 238000000034 method Methods 0.000 title description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 31
- 230000008685 targeting Effects 0.000 claims abstract description 16
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims abstract description 7
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 29
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical class C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 10
- 238000010168 coupling process Methods 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 7
- 229940099563 lactobionic acid Drugs 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical class O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 claims description 6
- 229930182830 galactose Natural products 0.000 claims description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 15
- 229940002612 prodrug Drugs 0.000 abstract description 8
- 239000000651 prodrug Substances 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 239000003937 drug carrier Substances 0.000 abstract description 3
- 229940009456 adriamycin Drugs 0.000 abstract 5
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 229930195573 Amycin Natural products 0.000 description 19
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000006268 Sarcoma 180 Diseases 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- DSLBDPPHINVUID-REOHCLBHSA-N (2s)-2-aminobutanediamide Chemical compound NC(=O)[C@@H](N)CC(N)=O DSLBDPPHINVUID-REOHCLBHSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 108010052780 polyasparagine Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- -1 Gal-PHEA-suc Chemical compound 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- NHISOSFLESCFIC-UHFFFAOYSA-N n-(2-hydroxypropyl)-n-methylprop-2-enamide Chemical compound CC(O)CN(C)C(=O)C=C NHISOSFLESCFIC-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101922251A CN101195032B (zh) | 2007-12-21 | 2007-12-21 | 聚天冬酰胺衍生物与阿霉素偶联物的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101922251A CN101195032B (zh) | 2007-12-21 | 2007-12-21 | 聚天冬酰胺衍生物与阿霉素偶联物的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101195032A CN101195032A (zh) | 2008-06-11 |
CN101195032B true CN101195032B (zh) | 2010-12-29 |
Family
ID=39545776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101922251A Active CN101195032B (zh) | 2007-12-21 | 2007-12-21 | 聚天冬酰胺衍生物与阿霉素偶联物的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101195032B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102875651B (zh) * | 2012-09-27 | 2014-06-18 | 亚飞(上海)生物医药科技有限公司 | 抗肿瘤靶向激活的多肽阿霉素、其制备方法和用途 |
CN106344930B (zh) * | 2015-07-16 | 2021-08-17 | 亚飞(上海)生物医药科技有限公司 | 分子定点靶向和激活的短肽阿霉素的制备和用途 |
-
2007
- 2007-12-21 CN CN2007101922251A patent/CN101195032B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN101195032A (zh) | 2008-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103705940B (zh) | 一种天然活性药物-多糖靶向复合物的制备及其抗肿瘤的应用 | |
CN104530256B (zh) | 透明质酸维生素e琥珀酸酯聚合物及其制备和用途 | |
CN105727309A (zh) | 双敏感两亲性多糖-阿霉素偶联物及其药学组合物的制备和应用 | |
CN101791411A (zh) | 两亲性多糖偶联物及其药物组合物的制备和应用 | |
Hu et al. | Acid-responsive PEGylated branching PLGA nanoparticles integrated into dissolving microneedles enhance local treatment of arthritis | |
CN101240002A (zh) | 脂肪酰氨基酰阿糖胞苷缀合物、其制备方法和应用 | |
CN109875964B (zh) | 一种阿霉素无载体纳米药物的制备及其应用 | |
CN107998082A (zh) | 一种还原响应聚合物囊泡纳米药物在制备脑肿瘤治疗药物中的应用 | |
CN101134109A (zh) | 一种抗癌前药及其制备方法和用途 | |
CN102260356A (zh) | 一种用作基因载体的壳聚糖衍生物及其制备方法和用途 | |
CN111333692B (zh) | 一种白桦脂酸衍生物及其制备方法和应用 | |
CN112961188A (zh) | 一种四价铂前药苄达酸铂、其制剂及制备方法和应用 | |
Cheng et al. | Improve bile duct-targeted drug delivery and therapeutic efficacy for cholangiocarcinoma by cucurbitacin B loaded phospholipid complex modified with berberine hydrochloride | |
CN108524533A (zh) | 一种化合物用作抗肿瘤药物增效剂和逆转剂 | |
CN104208704B (zh) | 一种pH敏感的碳纳米管靶向递药体系的制备方法 | |
CN108126210A (zh) | 一种单靶向还原响应囊泡纳米药物在制备脑肿瘤治疗药物中的应用 | |
CN108653745B (zh) | 一种透明质酸前药及其制备方法和在透皮给药中的应用 | |
CN102525929A (zh) | 甘草次酸修饰的汉黄芩素脂质体制剂及其制备方法 | |
CN101195032B (zh) | 聚天冬酰胺衍生物与阿霉素偶联物的制备方法及其应用 | |
CN103933016B (zh) | 一种辣椒碱三元纳米胶束及其制法和用途 | |
CN107998081A (zh) | 一种靶向还原响应囊泡纳米药物在制备脑肿瘤治疗药物中的应用 | |
CN108542895A (zh) | 透明质酸-姜黄素-聚乙二醇载体制备方法及其应用 | |
CN104398504A (zh) | 一种去氧鬼臼毒素类药物的药物组合物及其制备方法和制剂 | |
CN109675052B (zh) | 生物点击触发的高效靶向偶联物及其多元组合物、制备方法和应用 | |
CN110665009B (zh) | 一种促肿瘤血管正常化纳米化吉西他滨及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HEFEI BOTAI PHARMACEUTICAL BIOTECHNOLOGY DEVELOPME Free format text: FORMER OWNER: NANJING UNIVERSITY Effective date: 20110511 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210097 NO. 22, HANKOU ROAD, NANJING CITY, JIANGSU PROVINCE TO: 230088 ROOM 507/509, BUILDING 7, VENTURE SERVICE CENTER, NO. 102, KEXUE AVENUE, HIGH-TECH. ZONE, HEFEI CITY, ANHUI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110511 Address after: 230088, 507/509 building, building 7, Venture Service Center, 102 science Road, hi tech Zone, Anhui, Hefei Patentee after: Hefei Botai Pharmaceutical Biotechnology Development Co., Ltd. Address before: 210097 Hankou Road, Jiangsu city of Nanjing province No. 22 Patentee before: Nanjing University |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170523 Address after: 230088, Hefei province high tech Zone Innovation Avenue 2800, innovation industry park two, E District 1, B, building 2, Anhui Patentee after: Hefei Jian Jian Pharmaceutical Technology Co., Ltd. Address before: 230088, 507/509 building, building 7, Venture Service Center, 102 science Road, hi tech Zone, Anhui, Hefei Patentee before: Hefei Botai Pharmaceutical Biotechnology Development Co., Ltd. |
|
TR01 | Transfer of patent right |